Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 6
Original Research
Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 10,047 | Dovepress* | 9,052+ | 1,975 | 11,027 | |
| PubMed Central* | 995 | 484 | 1,479 | ||
| Totals | 10,047 | 2,459 | 12,506 | ||
|
*Since 1 April 2014 +Since July 2016 |
|||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 4 | 0 | 0 | 0 | 2 | 2 |
View citations on PubMed Central and Google Scholar